| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
67,520,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amylyx Pharmaceuticals is engaged in the development of therapies that change the treatment paradigm for amyotrophic lateral sclerosis, and a range of neurodegenerative diseases. Co. is pursuing commercialization of its product candidate, AMX0035, which is a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. Co. is also developing AMX0035 for other neurodegenerative diseases including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, Friedreich's ataxia, Leigh's syndrome and Leber's hereditary optic neuropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
10,000 |
205,000 |
209,000 |
| Total Buy Value |
$37,005 |
$37,005 |
$474,199 |
$534,079 |
| Total People Bought |
1 |
1 |
5 |
5 |
| Total Buy Transactions |
1 |
1 |
6 |
7 |
| Total Shares Sold |
90,463 |
138,210 |
205,994 |
288,273 |
| Total Sell Value |
$308,977 |
$494,469 |
$697,365 |
$2,600,378 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
9 |
15 |
20 |
32 |
| End Date |
2025-02-09 |
2024-11-08 |
2024-05-10 |
2023-05-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mazzariello Gina |
Chief Legal Officer |
• – – |
2025-03-31 |
4 |
S |
$3.48 |
$31,954 |
D/D |
(9,192) |
187,969 |
|
- |
|
| Frates James M |
Chief Financial Officer |
• – – |
2025-03-31 |
4 |
S |
$3.47 |
$37,806 |
D/D |
(10,896) |
290,988 |
|
- |
|
| Cohen Joshua B |
Co-Chief Executive Officer |
• • – |
2025-03-31 |
4 |
S |
$3.47 |
$74,482 |
D/D |
(21,490) |
3,355,280 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-03-31 |
4 |
S |
$3.46 |
$74,454 |
D/D |
(21,490) |
3,355,276 |
|
- |
|
| Bedrosian Camille L |
Chief Medical Officer |
• – – |
2025-03-31 |
4 |
S |
$3.47 |
$43,082 |
D/D |
(12,425) |
194,375 |
|
- |
|
| Zeiher Bernhardt G |
|
– • – |
2025-03-20 |
4 |
B |
$3.70 |
$37,005 |
D/D |
10,000 |
10,000 |
0.01 |
- |
|
| Mazzariello Gina |
Chief Legal Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
63,851 |
197,161 |
|
- |
|
| Bedrosian Camille L |
Chief Medical Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
68,420 |
206,800 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
180,118 |
3,376,766 |
|
- |
|
| Frates James M |
Chief Financial Officer |
• – – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
68,420 |
301,884 |
|
- |
|
| Cohen Joshua B |
Co-Chief Executive Officer |
• • – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
180,118 |
3,376,770 |
|
- |
|
| Mazzariello Gina |
Chief Legal Officer |
• – – |
2025-03-03 |
4 |
S |
$3.12 |
$5,022 |
D/D |
(1,611) |
133,310 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-03-03 |
4 |
S |
$3.15 |
$14,483 |
D/D |
(4,595) |
3,196,648 |
|
- |
|
| Cohen Joshua B |
Co-Chief Executive Officer |
• • – |
2025-03-03 |
4 |
S |
$3.17 |
$14,549 |
D/D |
(4,595) |
3,196,652 |
|
- |
|
| Mazzariello Gina |
Chief Legal Officer |
• – – |
2025-02-24 |
4 |
S |
$3.15 |
$13,145 |
D/D |
(4,169) |
134,921 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-02-05 |
4 |
OE |
$1.57 |
$57,007 |
D/D |
36,310 |
3,201,243 |
|
- |
|
| Cohen Joshua B |
Co-Chief Executive Officer |
• • – |
2025-02-03 |
4 |
S |
$3.47 |
$41,108 |
D/D |
(11,851) |
3,201,247 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-02-03 |
4 |
S |
$3.47 |
$41,104 |
D/D |
(11,855) |
3,164,933 |
|
- |
|
| Mazzariello Gina |
Chief Legal Officer |
• – – |
2025-02-03 |
4 |
S |
$3.49 |
$12,839 |
D/D |
(3,678) |
139,090 |
|
- |
|
| Milne George M Jr |
|
– • – |
2025-01-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
27,910 |
830,661 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2025-01-06 |
4 |
S |
$4.04 |
$30,202 |
D/D |
(7,471) |
3,176,788 |
|
- |
|
| Cohen Joshua B |
Co-Chief Executive Officer |
• • – |
2025-01-06 |
4 |
S |
$4.05 |
$30,232 |
D/D |
(7,471) |
3,213,098 |
|
- |
|
| Bedrosian Camille L |
Chief Medical Officer |
• – – |
2024-12-02 |
4 |
S |
$5.54 |
$30,007 |
D/D |
(5,421) |
138,380 |
|
- |
|
| Klee Justin B. |
Co-Chief Executive Officer |
• • – |
2024-11-04 |
4 |
OE |
$1.57 |
$99,993 |
D/D |
63,690 |
3,184,259 |
|
- |
|
| Mazzariello Gina |
Chief Legal Officer |
• – – |
2024-09-30 |
4 |
S |
$3.20 |
$27,840 |
D/D |
(8,709) |
142,768 |
|
- |
|
133 Records found
|
|
Page 1 of 6 |
|
|
